Safety of recombinant factor VIIa in patients under extracorporeal membrane oxygenation

European Journal of Cardio-thoracic Surgery

Volumn 49, Issue 1, 2016, Pages 78-84

  Anselmi, Amedeo ^a,b   Guinet, Patrick ^a   Ruggieri, Vito Giovanni ^a,b   Aymami, Marie ^a   Lelong, Bernard ^a   Granry, Solène ^a   Malledant, Yannick ^a   Tulzo, Yves Le ^a   Gueret, Pierre ^a   Verhoye, Jean Philippe ^a,b   Flecher, Erwan ^a,b  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Bleeding; Extracorporeal membrane oxygenation; Outcomes

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ADULT; ARTERY DISEASE; ARTICLE; BRONCHUS DISEASE; CAROTID ARTERY DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SAFETY; EXTRACORPOREAL OXYGENATION; FEMALE; HEART SURGERY; HEART TRANSPLANTATION; HUMAN; INFECTIOUS COMPLICATION; INTENSIVE CARE UNIT; MALE; MEDIASTINUM DISEASE; MORTALITY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RETROPERITONEAL DISEASE; RETROSPECTIVE STUDY; SUBCLAVIAN ARTERY; THROMBOEMBOLISM; TRACHEA DISEASE; VENO ARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION; VENO VENOUS EXTRACORPOREAL MEMBRANE OXYGENATION; ADVERSE EFFECTS; AGED; BLEEDING; CASE CONTROL STUDY; CHEMICALLY INDUCED; FACTUAL DATABASE; FOLLOW UP; HEART FAILURE; HOSPITAL MORTALITY; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT SAFETY; PROCEDURES; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; TERTIARY CARE CENTER; TREATMENT OUTCOME;

ADULT; AGED; CARDIAC SURGICAL PROCEDURES; CASE-CONTROL STUDIES; DATABASES, FACTUAL; EXTRACORPOREAL MEMBRANE OXYGENATION; FACTOR VIIA; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEMORRHAGE; HOSPITAL MORTALITY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT SAFETY; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TERTIARY CARE CENTERS; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84958229150     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezv140     Document Type: Article

References (24)

1. Rastan AJ, Dege A, Mohr M, Doll N, Falk V, Walther T et al. Early and late outcomes of 517 consecutive adult patients treated with extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock. J Thorac Cardiovasc Surg 2010;139:302-11.
2. Heilmann C, Geisen U, Beyersdorf U, Nakamura L, Benk C, Trummer G et al. Acquired von Willebrand syndrome in patients with extracorporeal life support (ECLS). Intensive Care Med 2012;38:62-8.
3. Oliver WC. Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth 2009;13:154-75.
4. Beckmann A, Benk C, Beyersdorf F, Haimerl G, Merkle F, Mestres C et al. Position article for the use of extracorporeal life support in adult patients. Eur J Cardiothorac Surg 2011;40:676-81.
5. Okonta K, Ewin F, Falase B. Is recombinant activated factor VII effective in the treatment of excessive bleeding after pediatric cardiac surgery? Interact CardioVasc Thorac Surg 2012;15:690-5.
6. Agarwal H, Bennett J, Churchwell K, Christian KG, Drinkwater DC, He Y et al. Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg 2007;84:161-9.
7. Repessé X, Au SM, Bréchot N, Trouillet JL, Leprince P, Chastre J et al. Recombinant factor VIIa for uncontrollable bleeding in patients with extracorporeal membrane oxygenation: report on 15 cases and literature review. Crit Care 2013;17:R55.
8. Flécher E, Anselmi A, Corbineau H, Langanay T, Verhoye JP, Félix C et al. Current aspects of extracorporeal membrane oxygenation in a tertiary referral center: determinants of survival at follow-up. Eur J Cardiothorac Surg 2014;46:665-71.
9. Thiagarajan RR, Brogan TV, Scheurer MA, Laussen PC, Rycus PT, Bratton SL. Extracorporeal membrane oxygenation to support cardiopulmonary resuscitation in adults. Ann Thorac Surg 2009;87:778-85.
10. Brinkman S, Bakshshi-Raiez F, Abu-Hanna A, de Jonge E, Bosman RJ, Peelen DL et al. External validation of Acute Physiology and Chronic Health Evaluation IV in Dutch intensive care units and comparison with Acute Physiology and Chronic Health Evaluation II and simplified Acute Physiology Score II. J Crit Care 2011;26:105.e11-8.
11. Taylor FB, Kinasewitz GT. The diagnosis and management of disseminated intravascular coagulation. Curr Hemat Rep 2002;1:34-40.
12. Wang J, Han J, Jia Z, Zheng W, Shi J, Hou X et al. Early and intermediate results of rescue extracorporeal membrane oxygenation in adult cardiogenic shock. Ann Thorac Surg 2009;88:1897-903.
13. Marasco SF, Lukas G, McDonald M, McMilan J, Ihle B. Review of ECMO (extracorporeal membrane oxygenation) support in critically ill adult patients. Heart Lung Circ 2008;17(Suppl 4):S41-7.
14. Brogan TV, Thiagarajan RR, Rycus PT, Bratlett RH, Bratton SL. Extracorporeal membrane oxygenation in adults with severe respiratory failure: a multicenter database. Intensive Care Med 2009;35:2105-14.
15. Jurlander B, Thim L, Klausen NK, Persson E, Kjalke M, Rexen P et al. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin Thromb Hemost 2001;27:373-84.
16. Monroe DM, Hoffman M, Oliver JA, Roberts RH. Platelet activity of highdose factor VIIa is independent of tissue factor. Br J Hematol 1997;99:542-7.
17. Veldman A, Neuhauser C, Akintuerk H, Thul J, Gehron J, Schranz D et al. rFVIIa in the treatment of persistent hemorrhage in pediatric patients on ECMO following surgery for congenital heart disease. Pediatr Anaesth 2007;17:1176-81.
18. Von Depka M. NovoSeven: mode of action and use in acquired haemophilia. Intensive Care Med 2002;28(Suppl 2):S222-7.
19. Bui JD, Despostis GD, Trulock EP, Patterson GA, Goodnough LT. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg 2002;124:852-4.
20. Saeed D, Albert A, Kamiya H, Maxhera B, Westenfeld R, Lichtenberg A. Five days of no anticoagulation of antiplatelet therapy and NovoSeven administration in a HeartWare HVAD patient. Artif Organs 2012;36:751-3.
21. Syburra T, Lachat M, Genoni M, Wilhelm M. Fatal outcome of recombinant factor VIIa in heart transplantation with extracorporeal membrane oxygenation. Ann Thorac Surg 2010;89:1643-5.
22. Matsuo Y, Cassar A, Li J, Flammer AJ, Choi BJ, Hermann J et al. Repeated episodes of thrombosis as a potential mechanism of plaque progression in cardiac allograft vasculopathy. Eur Heart J 2013;34:2905-15.
23. Gill R, Herberston M, Vuylsteke A, Olsen P, von Heymann C, Mythen M et al. Safety and efficacy of recombinant activated factor VII-a randomised placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 2009;120:21-7.
24. Alfirevic A, Duncan A, You J, Lober C, Soltesz E. Recombinant factor VII is associated with worse survival in complex cardiac surgical patients. Ann Thorac Surg 2014;98:618-24.